GB Sciences is using artificial intelligence to improve cannabis research

318 0

The cannabis company turns to technology to lead cannabis studies

The use of artificial intelligence (AI) is helping to improve processes in many areas of different industries today, and apparently, cannabis is no exception. GB Sciences is currently on the cusp when it comes to cutting-edge biopharmaceutical research with its new AI-accelerated drug discovery platform PhAROS, which in simple words, is considered a phytomedical analytics that is responsible for optimizing research at scale.

Drug discovery can be taken to another level through this platform, which is based on a scientific portal and a virtual research environment that greatly facilitates the work of all researchers and developers in the field. Based on the data analysis capabilities and all the automated learning included in PhAROS, a lot of human labor and money invested can be reduced so that novel plant-inspired formulations can reach the market as soon as possible.

At the time this proprietary platform first came into use, GB Sciences did so using its own database that described the active ingredients of the cannabis plant, but over time, the amount of data stored has expanded and its range is now broader. The idea is to be able to reach the conclusion of which natural plants today can have an impact on the medical industry, and that is why cannabis has also had a priority focus in this type of research carried out in this company.

“Our company has assembled the ultimate toolkit to create the ‘Future of Medicine’: artificial intelligence technology, plant-based medicine, and hard science. More than anything else, the use of AI pushes biomedical research beyond simplistic approaches to treating human disease as if a single ‘magic bullet’ could cure a complex disease,” said Andrea Small-Howard, president and chief scientific officer of GB Sciences.